Phospho-flow Cytometry for Neoplastic Cell Identification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current laboratory testing methods are limited in analyzing intact live cells and are insufficient for identifying signaling activation profiles that define certain cell types, particularly neoplastic cell subsets, due to the inability to assess functional attributes of rare cell types and the compromise of surface markers during cell fixation processes.
Innovation Solution
A method involving the selection of markers for multiplexed assessment of surface and intracellular markers across multiple tubes, where surface markers are tested on live cells and IC markers are evaluated after fixation, allowing for the detection and quantification of abnormal cell types by phospho-flow cytometry, and a unique sample preparation method incorporating pre-fixation cooling to enhance fold-change measurement.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cells are fixed to preserve signaling states, then signaling biomarker detection is improved, but surface marker integrity deteriorates
Solution Approach 1:
The patent divides the cell population into separate groups: one portion is fixed to preserve intracellular signaling states, while another portion remains unfixed to maintain surface marker integrity. This segmentation allows simultaneous optimization of both detection types without mutual interference, resolving the contradiction between fixing for signaling detection and maintaining surface markers.
Solution Approach 2:
The patent extracts the conflicting requirements by separating the analysis into distinct experimental portions. Surface markers are assessed on live/unfixed cells, while intracellular signaling markers are assessed on fixed cells. This extraction of the contradiction into separate experimental streams allows each to be optimized independently.
2Measurement precision
If multiple surface markers are assessed simultaneously, then cell identification accuracy is improved, but the number of required antibodies increases
Solution Approach 1:
The patent combines multiple antibody assessments into a single multiparameter flow cytometry experiment. By using fluorescently labeled antibodies with different emission spectra, the invention enables simultaneous detection of multiple surface markers (lineage markers, maturation markers, activation markers) in one tube, reducing the total number of separate antibody preparations needed while maintaining high cell identification accuracy.
3Productivity
If fluorescent flow cytometry is used for multiparameter analysis, then simultaneous marker evaluation is improved, but spectral overlap and compensation complexity increase
Solution Approach 1:
The patent utilizes the spectral properties of different fluorochromes as varying parameters to resolve overlap issues. By carefully selecting fluorochrome combinations with distinct emission spectra and configuring detector wavelengths accordingly, the invention manages spectral overlap through parameter optimization rather than avoiding multiparameter analysis entirely. This allows simultaneous evaluation of multiple markers while controlling compensation complexity through systematic parameter selection.
4Quantity of substance
If tandem dyes are used to increase marker capacity, then the number of detectable markers is improved, but dye stability deteriorates
Solution Approach 1:
The patent acknowledges the limited stability of tandem dyes but compensates by optimizing experimental timing and sample handling procedures. The invention uses tandem dyes strategically for markers where temporary signal is acceptable, while relying on more stable fluorochromes for critical measurements. This selective approach allows increased marker capacity while managing the inherent instability of tandem dyes through procedural controls.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables accurate identification and characterization of neoplastic cell types by stabilizing baseline signaling activity and enhancing the detection of oncogenic signaling activities, improving the accuracy of cell type identification and prognostic assessment in hematological disorders.
Implementation Method 1
incorporating pre-fixation cooling to enhance fold-change measurement
Data Source
AI summary
The present invention recognizes that current clinical laboratory testing methods for multiparametric single cell analysis are limited to analysis of intact live cells, and are insufficient for identification of signaling activation profile defining certain cell types, including but not limited to neoplastic and immunologically activated cell subsets. One aspect of the present invention generally relates to marker selection in panels to include proteins routinely assessed in standard FCM, while preferably also incorporating markers for surface receptor proteins within activated signaling cascades. A further aspect of the present invention generally relates to panel design for the following indications in neoplastic and non-neoplastic clinical applications as examples of the technology: (a) identification of CML progenitor cell subsets in the setting of disease recurrence after treatment discontinuation or relapse due to treatment resistance, and (b) characterization of activated basophils to predict the severity of an allergic response. Another aspect of the present invention generally relates to methods to measure levels of surface and IC biomarkers in separate or combined assays for robust characterization of each or select cell compartment, and data analysis based on results from each or all method(s) used for optimal detection of the markers. A further aspect of the present invention generally relates to the identification and profiling of cell subpopulations based on analysis of surface markers including those associated with lineage and maturation of cell types and receptor proteins, and the corresponding IC phosphoproteins including those in activated signaling cascades to predict certain disease states or response to treatment.